Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years

Summary

A Phase 2 clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in the pediatric population aged 2 months (minimum 42 days) to 5 years. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, positive controlled phase 2 clinical trial.

Timeline

Start

2025-11-25

Primary completion

2026-09

Completion

2027-12

Drugs

Indications